The Trump Administration’s deregulatory response to COVID-19 is temporary and will not have a lasting impact on U.S. health care.
Experts suggest changing Medicare’s payment structure to encourage physicians to pursue primary care specialties.
Given its importance in scientific development, human subjects research requires close regulatory attention.
The court ruling striking down the Affordable Care Act may get in the way of making drugs affordable.
Scholars say constitutionally shaky infectious disease regulations must yield to better prevention programs.
A federal judge strikes a blow to two states’ Medicaid work requirements.
National injunction stops corporations from claiming religious or moral exemptions to birth control coverage.
States should shift incentives to reduce nonmedical exemptions while respecting the choice not to vaccinate.
Scholar urges new regulatory frameworks for recognizing nonbinary individuals under the law.
The Trump Administration encourages states to use “innovation waivers” to find new ways to lower costs.
HIPAA does not stop health care providers from disclosing patient information to provide better care.
A proposed requirement to display drug list prices in advertisements draws controversy.